Last reviewed · How we verify
NCT06672822: STSINJ
Intralesional Injection of STS in Treatment of Calcinosis
Phase 2 trial testing Sodium Thiosulfate (STS) in Systemic Sclerosis (SSc) in 20 participants. Currently enrolling.
31 August 2028
Quick facts
| Lead sponsor | Robyn T. Domsic, MD, MPH |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 17 March 2025 |
| Primary completion | 31 August 2028 |
| Estimated completion | 1 May 2029 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Sodium Thiosulfate (STS) — full drug profile →
Conditions studied
- Systemic Sclerosis (SSc) — all drugs for Systemic Sclerosis (SSc) →
- Dermatomyositis — all drugs for Dermatomyositis →
- Mixed Connective Tissue Disease (MCTD) — all drugs for Mixed Connective Tissue Disease (MCTD) →
- Calcinosis — all drugs for Calcinosis →
Sponsor
Robyn T. Domsic, MD, MPH
Who can join
18 and older, any sex, with Systemic Sclerosis (SSc) or Dermatomyositis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The specific objective of this study is to perform a small, open-label study to assess the safety and efficacy of intralesional, subcutaneous injection of STS on calcinosis symptoms and lesion size in systemic sclerosis (SSc), mixed connective tissue disease (MCTD) and dermatomyositis (DM) patients. Injection will be guided by ultrasound, lesion size assessed by ultrasound, and symptom burden by patient-reported outcome measures.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06672822
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sodium Thiosulfate (STS)
Trials testing the same drug.
- NCT01369641 — The Effect of Sodium Thiosulfate Eardrops on Hearing Loss in Patients Who Receive Cisplatin Therapy · NA · terminated
- NCT04132882 — A Compassionate Use Program to Provide Access to Sodium Thiosulfate · available
Other recruiting trials for Systemic Sclerosis (SSc)
Currently open trials in the same condition.
- NCT07526350 — MTS109 in Patients With Refractory Autoimmune Diseases · EARLY_PHASE1 · recruiting
- NCT07087912 — Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases · Phase 4 · recruiting
- NCT07413341 — A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases · Phase 1 · recruiting
- NCT07360808 — Safety and Efficacy of Adipose-Derived Regenerative Cells (ADRCs) for Improving Hand Dysfunction in Systemic Sclerosis · NA · recruiting
- NCT07292961 — Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed Wi · NA · recruiting
Other Robyn T. Domsic, MD, MPH trials
Trials by the same sponsor.
- NCT04854850 — Apollo Device for Fatigue in Systemic Sclerosis · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06672822 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Robyn T. Domsic, MD, MPH
- Last refreshed: 8 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06672822.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing